home / stock / prax / prax news


PRAX News and Press, Praxis Precision Medicines Inc.

Stock Information

Company Name: Praxis Precision Medicines Inc.
Stock Symbol: PRAX
Market: NASDAQ
Website: praxismedicines.com

Menu

PRAX PRAX Quote PRAX Short PRAX News PRAX Articles PRAX Message Board
Get PRAX Alerts

News, Short Squeeze, Breakout and More Instantly...

PRAX - Baird sees Jazz study failure as positive for rival Praxis

2024-06-21 14:41:42 ET More on Praxis Precision Medicines Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing Praxis Precision Medicines announces proposed public offering Praxis gains after mid-stage data for epilepsy candidate Seeking Alph...

PRAX - Overweight Recommendation Issued On PRAX By Piper Sandler

2024-05-20 14:30:05 ET Piper Sandler analyst issues OVERWEIGHT recommendation for PRAX on May 20, 2024 12:01PM ET. The previous analyst recommendation was Overweight. PRAX was trading at $44.93 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

PRAX - Buy Recommendation Issued On PRAX By Jefferies

2024-05-16 16:30:03 ET Jefferies analyst issues BUY recommendation for PRAX on May 16, 2024 02:01PM ET. The previous analyst recommendation was Buy. PRAX was trading at $45.32 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...

PRAX - Praxis Precision Medicines GAAP EPS of -$2.84 misses by $0.75, revenue of $0.43M misses by $1.33M

2024-05-13 08:48:42 ET More on Praxis Precision Medicines Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing Praxis Precision Medicines announces proposed public offering Praxis gains after mid-stage data for epilepsy candidate Seeking Alph...

PRAX - Expected US Company Earnings on Monday, May 13th, 2024

Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...

PRAX - Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively Continued strong recruitment for the pivotal Essential3 trials in Essential Tremor (ET), with over 50,000 pre-screening forms and over 7,00...

PRAX - Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition i...

PRAX - How the (PRAX) price action is used to our Advantage

2024-04-26 16:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

PRAX - Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...

PRAX - (PRAX) Trading Report

2024-04-06 21:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Next 10